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patients is poor. In addition, the study demonstrated that the risk of refracture is 
associated with the compliance and persistence with bisphosphonate therapy in 
Taiwan. The compliance and persistence issues for osteoporosis treatment warrant 
much more attention. 
MUSCULAR-SKELETAL DISORDERS – Cost Studies
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OBJECTIVES: To assess comorbidity, quality of life (QOL), work/productivity loss, 
and medical resource utilization in patients with rheumatoid arthritis (RA). 
METHODS: Patients’ self-reported data were collected from 2009 National Health 
and Wellness Survey (NHWS). Survey samples represented major urban areas in 
China. QOL was measured by the physical component score (PCS) and mental com-
ponent score (MCS) of the Short Form-12 (SF-12) (mean score of 50 for general popu-
lation). Loss of work/productivity was measured by the validated Work Productivity 
and Activity Impairment (WPAI) instrument. Medical resource utilization was mea-
sured by health-care provider, emergency room (ER) visits and hospitalization in the 
past 6 months. Comparisons were made between respondents who suffer from RA 
(excluding psoriasis, psoriatic arthritis, or inﬂ ammatory bowel disease) versus respon-
dents without RA (non-RA group). RESULTS: Of the 13,307 survey respondents, 276 
(2.1%) were diagnosed with RA, and the average age was 46.6 years. There were 
more females in RA group (59.5%) versus non-RA group (50.7%). RA group reported 
more diagnosed comorbidities (insomnia 43%, hypertension 24.7%, migraine 24.1%, 
allergies 23.4%, arrhythmia 22.8%, gingivitis 22.5%, dermatitis 18.9%, osteoporosis 
16.9%, anemia 15.5%, bronchitis 13.9%, asthma 13.7%), lower mean scores of PCS 
(42.7 ` 48.5) and MCS (42.4 vs. 46.0), more patients visited health-care providers 
(83.3% vs. 56.3%), ER (48.5% vs. 18.9%) and hospitalized (25.0% vs. 7.0%) in the 
past 6 months compared to non-RA group. Also, RA group reported 37.8% work/
productivity loss (absenteeism and presenteeism) and 36.6% impairment in daily 
activity compared to 22.7% and 22.6% in non-RA group. All comparisons between 
RA and non-RA groups were statistically signiﬁ cant at P < 0.05. CONCLUSIONS: 
From the China NHWS results, RA patients suffer from impairment in quality of life, 
work/productivity loss, more comorbidities and use of medical services. The ﬁ ndings 
indicate there is still an unmet medical need in RA patients in China. 
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OBJECTIVES: In the Judo-therapeutic ﬁ eld, their costs are partly covered by National 
Health Insurance System via fee-for-service reimbursement, which does not necessarily 
reﬂ ect actual costs. Therefore, the actual situation of medical practice in Judo-therapy 
Clinics (bone-setting clinics) is analyzed by comparison between the actual costs cal-
culated by micro-costing methods and .reimbursement cost calculated by fee-for-
service system. METHODS: The basis of this study is a bidirectional evaluation of 
single medical intervention in terms of actual cost and reimbursed cost for single 
treatment with following methods: 1) All receipts are collected from the participating 
bone-setting clinics for a ﬁ xed period of time; 2) Along with collection of receipts, 
information on the medical interventions is recorded by region with regard to “how 
long” and “who” performed them; 3) The tentative cost of medical intervention is 
calculated based on the data in 2) above and the data of wage for the engaged persons. 
In other words, the tentative cost is calculated as the practitioner’s wage per unit time 
multiplied by the time consumed; 4) The cost-based amount of individual medical 
intervention is calculated by adding indirect costs (wage for other staff than practitio-
ner, cost for operation/maintenance of judo-therapy clinic) to the data in 3); and 5) 
Standard critical paths are made for several diseases, based on which medical expense 
for each therapy model is calculated in terms of both receipt-based amount and cost-
based amount, and a comparison of amount is made between them. RESULTS: 
Therapies in a total of 1646 regions were recorded, based on which a comparison was 
made using four diseases (lumbar sprain, neck sprain, femoral contusion, back contu-
sion) as models. The receipt-based medical expense was JPY9030 (US$100) for all 
diseases, while the cost-based medical expense widely varied from JPY22,057 to 
JPY22,950 (US$245 to US$255). CONCLUSIONS: There was a signiﬁ cant difference 
between the insurance beneﬁ t amount and the actual cost of medical intervention in 
judo-therapy. 
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OBJECTIVES: Facing scarce data in Thailand on hospital costs of osteoporotic frac-
tures, we examined repeated fractures and hospital costs incurred over 1 year from a 
primary osteoporotic hip fracture hospitalization occurred in postmenopausal women 
with or without comorbidities at Bumrungrad International Hospital in Bangkok. 
METHODS: Hospital admissions for primary hip fracture coded ICD-10 S 72.1 in 
post-menopausal women, aged 55 or older, were collected from January 2007 to 
January 2009. The hip fracture comorbidities considered were hypertension, type 2 
diabetes, cardiovascular disease and their combinations. The repeated fractures within 
6 or 12 months after ﬁ rst admission were documented. All direct medical costs were 
retrieved from the hospital database looking at 1-year follow-up period. Statistical 
analysis employed unpaired t-test, Mann–Whitney U test and multivariate analysis for 
comparison of outcomes, costs and correlations to comorbidities. RESULTS: A total 
of 59 hospital admissions for diagnosed osteoporotic primary hip fracture in post-
menopausal women were screened. Patients’ mean age (SD) was 74.6 (7.7) years old, 
the mean hospital follow-up (SD) was 246.7 (77.5) days and the mean hospitalization 
duration (SD) was 17.0 (12.2) days. Patients at screening with and without comorbidi-
ties had similar characteristics including the types of fractures. The group with comor-
bidities was at higher relative risks of repeated fractures at 6 and 12 months follow-up 
compared to the group without comorbidities (1.13 vs. 0.91, P = 0.016; 1.10 vs. 0.94, 
P = 0.273, respectively) with consequently higher health-care utilization cost with 
564,300 THB/patient/year versus 374,200 THB/patient/year, P = 0.043. The cost of 
all type drugs for both groups was only 8–10% of the total illness cost. CONCLU-
SIONS: In osteoporotic post-menopausal women admitted at hospital for primary hip 
fracture, comorbidities increased risks of repeated fractures hospitalization as well 
as hospital costs. The cost of drugs was marginal among hospital costs of 
osteoporosis. 
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OBJECTIVES: To evaluate the cost-effectiveness of bisphosphonates (alendronate, 
risedronate, ibandronate, zoledronic acid), raloxifene, calcitonin and strontium 
ranelate, with a combination of calcium and Vitamin D as comparator, for the preven-
tion of osteoporosis-related fractures in Thai post-menopausal women. METHODS: 
A Markov state transition model with 1-year cycle length was designed to simulate 
the cost-effectiveness of seven osteoporosis treatment interventions, compared with 
calcium and vitamin D, in Thai post-menopausal women aged 50–70 years. The model 
health states were categorized as osteopenia/no fracture, hip fracture, vertebral frac-
ture, post-hip fracture, post-vertebral fracture and death. Treatment effects were 
obtained from published literature. The analysis was conducted using a societal per-
spective and included direct medical, direct nonmedical and indirect costs. Uncertainty 
was investigated by a probabilistic Monte Carlo simulation. Treatment outcomes were 
measured in terms of number of fractures avoided, number of life-years gained and 
quality-adjusted life-years (QALY) gained. Cost-effectiveness was deﬁ ned as an ICER 
of less than 300,000 Baht (an incremental cost of ≤300,000 Baht for an outcome of 
no fracture for 1 year). RESULTS: 1) For patients with no prior fracture (primary 
prevention), zoledronic acid is cost-effective at ≥65 years, alendronate, risedronate and 
ibandronate at ≥70 years. 2) For patients with prior vertebral fracture (secondary 
prevention), zoledronic acid is cost-effective at ≥50 years, alendronate, risedronate and 
ibandronate at ≥55 years, raloxifene and strontium ranelate at ≥60 years; and 3) For 
patients with prior non-vertebral fractures, zoledronic acid is cost-effective at ≥60 
years, alendronate at ≥65 years, and risedronate and ibandronate at ≥70 years. CON-
CLUSIONS: Zoledronic acid, followed by other bisphosphonates, is the most cost-
effective treatment option for both primary and secondary fracture prevention in Thai 
postmenopausal women with osteoporosis. These ﬁ ndings should be implemented in 
the government policy for selecting appropriate anti-osteoporotic drugs and reim-
bursement support strategy for Thai postmenopausal women with osteoporosis. 
PMS8
COST-EFFECTIVENESS OF RISEDRONATE FOR CORTICOSTEROID-
INDUCED OSTEOPOROSIS IN AUSTRALIA
Liew D1, Gonzalo F2, Lewis T3
1The University of Melbourne, Fitzroy, Victoria, Australia; 2Sanoﬁ -Aventis Australia Pty 
Limited, Macquarie Park, Australia; 3Sanoﬁ -Aventis Australia Pty Ltd, Macquarie Park, NSW, 
Australia
OBJECTIVES: We sought to determine, from the Australian health-care perspective, 
the cost-effectiveness of the bisphosphonate risedronate, relative to placebo, in pre-
venting vertebral fractures among patients with corticosteroid-induced osteoporosis. 
METHODS: A decision-analytic Markov model was developed to simulate the onset 
